Wie hoch ist der Preis für U.S. Stem Cell, Inc. (USRM)

Preis für U.S. Stem Cell, Inc. (USRM) ist $0.00001

Wie hoch ist die Marktkapitalisierung für U.S. Stem Cell, Inc. (USRM)

Marktkapitalisierung für U.S. Stem Cell, Inc. (USRM) ist $6.42K

U.S. Stem Cell, Inc. (USRM) Ausstehende Aktien

U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and commercialization of autologous cellular therapies throughout the United States. Its core mission is to address a range of medical conditions, including both chronic and acute forms of heart damage, along with various vascular and autoimmune disorders. Among its leading experimental treatments are MyoCell, a clinical-stage therapy designed to utilize a patient's own muscle cells to regenerate scar tissue within the heart, aiming to enhance cardiac function for individuals suffering from chronic heart failure. Another significant offering is AdipoCell, a cell therapy also derived from the patient's own body, developed to combat conditions such as acute myocardial infarction, persistent heart ischemia, and ischemia affecting the lower limbs. The company's developmental pipeline also features MyoCell SDF-1, another autologous cellular therapy derived from muscle, intended to boost cardiac performance in chronic heart failure patients. Furthermore, U.S. Stem Cell is actively developing MyoCath, an innovative deflecting-tip needle injection catheter specifically engineered to deliver therapeutic cells directly into heart tissue, addressing chronic heart ischemia and congestive heart failure. Beyond its product development, the company offers a suite of services, including training programs in regenerative medicine and cell therapy for both medical professionals and patients. It also facilitates cell collection and storage, provides specialized kits for cell collection and treatment for both human and veterinary applications, and manages its own cell therapy clinic. This clinic delivers cellular treatments for a broad spectrum of conditions, such as neurological, autoimmune, orthopedic, and degenerative disorders. Previously known as Bioheart, Inc., the company adopted its current name, U.S. Stem Cell, Inc., in October 2015. Established in 1999, its corporate headquarters are situated in Sunrise, Florida.

Jahr	Ausstehende Aktien	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Ausstehende Aktien

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Ausstehende Aktien	Unterschied	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	0.00	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Unternehmen

Ausstehende Aktien

Unterschied

Land